Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial

DJ Khalaf; CK Kollmannsberger; BJ Eigl; K Noonan; D Wadhwa; A Attwell; B Keith; SL Ellard; L Le; ME Gleave; AW Wyatt; M Annala; KN Chi; S Taavitsainen; DL Finch; C Oja; J Vergidis; M Zulfiqar; K Sunderland; AA Azad

doi:10.1016/S1470-2045(19)30688-6

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial

DJ Khalaf, CK Kollmannsberger, BJ Eigl, K Noonan, D Wadhwa, A Attwell, B Keith, SL Ellard, L Le, ME Gleave, AW Wyatt, M Annala, KN Chi, S Taavitsainen, DL Finch, C Oja, J Vergidis, M Zulfiqar, K Sunderland, AA Azad

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

271 Sitaatiot (Scopus)

Alkuperäiskieli	Englanti
Sivut	p1730-1739
Julkaisu	The Lancet Oncology
Vuosikerta	20
Numero	12
DOI - pysyväislinkit	https://doi.org/10.1016/S1470-2045(19)30688-6
Tila	Julkaistu - 2019
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Julkaisufoorumi-taso

Jufo-taso 3

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

Pääsy asiakirjaan

10.1016/S1470-2045(19)30688-6

http://urn.fi/URN:NBN:fi:tuni-201912166909

Siteeraa tätä

Khalaf, DJ., Kollmannsberger, CK., Eigl, BJ., Noonan, K., Wadhwa, D., Attwell, A., Keith, B., Ellard, SL., Le, L., Gleave, ME., Wyatt, AW., Annala, M., Chi, KN., Taavitsainen, S., Finch, DL., Oja, C., Vergidis, J., Zulfiqar, M., Sunderland, K., & Azad, AA. (2019). Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial. The Lancet Oncology, 20(12), p1730-1739. https://doi.org/10.1016/S1470-2045(19)30688-6

@article{717f589de68542478e131ef753d6a138,

title = "Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial",

author = "DJ Khalaf and CK Kollmannsberger and BJ Eigl and K Noonan and D Wadhwa and A Attwell and B Keith and SL Ellard and L Le and ME Gleave and AW Wyatt and M Annala and KN Chi and S Taavitsainen and DL Finch and C Oja and J Vergidis and M Zulfiqar and K Sunderland and AA Azad",

year = "2019",

doi = "10.1016/S1470-2045(19)30688-6",

language = "English",

volume = "20",

pages = "p1730--1739",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier",

number = "12",

}

Khalaf, DJ, Kollmannsberger, CK, Eigl, BJ, Noonan, K, Wadhwa, D, Attwell, A, Keith, B, Ellard, SL, Le, L, Gleave, ME, Wyatt, AW, Annala, M, Chi, KN, Taavitsainen, S, Finch, DL, Oja, C, Vergidis, J, Zulfiqar, M, Sunderland, K & Azad, AA 2019, 'Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial', The Lancet Oncology, Vuosikerta 20, Nro 12, Sivut p1730-1739. https://doi.org/10.1016/S1470-2045(19)30688-6

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial. / Khalaf, DJ; Kollmannsberger, CK; Eigl, BJ et al.
julkaisussa: The Lancet Oncology, Vuosikerta 20, Nro 12, 2019, s. p1730-1739.

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial

AU - Khalaf, DJ

AU - Kollmannsberger, CK

AU - Eigl, BJ

AU - Noonan, K

AU - Wadhwa, D

AU - Attwell, A

AU - Keith, B

AU - Ellard, SL

AU - Le, L

AU - Gleave, ME

AU - Wyatt, AW

AU - Annala, M

AU - Chi, KN

AU - Taavitsainen, S

AU - Finch, DL

AU - Oja, C

AU - Vergidis, J

AU - Zulfiqar, M

AU - Sunderland, K

AU - Azad, AA

PY - 2019

Y1 - 2019

U2 - 10.1016/S1470-2045(19)30688-6

DO - 10.1016/S1470-2045(19)30688-6

M3 - Article

SN - 1470-2045

VL - 20

SP - p1730-1739

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 12

ER -